Part,  Chapter, Paragraph

 1   II,     5.  1.  1|                colon, endometrial and kidney cancer and, through the
 2   II,     5.  1.  1|              elderly smokers.~Chronic Kidney Disease and End Stage Renal
 3   II,     5.  4.  1|      including vision loss, nerve and kidney damage), and larger blood
 4   II,     5.  4.  1|           ability and thus leading to kidney failure (necessitating renal
 5   II,     5.  4.  2|            extremity amputation rates~Kidney disease in persons with
 6   II,     5.  4.  2|               pressure, blood lipids, kidney functions and microalbuminuria.
 7   II,     5.  4.  3|               pressure, blood lipids, kidney functions and microalbuminuria.
 8   II,     5.  7    |                          5.7. Chronic kidney disease and end stage renal~
 9   II,     5.  7.Acr|               Communities~CKD~Chronic Kidney Disease~ESRD~End Stage Renal
10   II,     5.  7.Acr|           Rate~HD~Haemodialysis~KDIGO~Kidney Disease Improving Global
11   II,     5.  7.  1|                Introduction~ ~Chronic kidney disease (CKD) is increasingly
12   II,     5.  7.  1|        treatment can prevent or delay kidney disease progression and
13   II,     5.  7.  1|       Chobanian et al, 2003; National Kidney Foundation, 2002-2006; Sarnak
14   II,     5.  7.  1|         definition established by the Kidney Disease Improving Global
15   II,     5.  7.  1|           KDIGO Definition of Chronic Kidney Disease~ ~ ~Structural or
16   II,     5.  7.  1|          months, as manifested by:~1. Kidney damage, with or without
17   II,     5.  7.  1|            abnormalities~• markers of kidney damage~urinary abnormalities (
18   II,     5.  7.  1|               imaging abnormalities~• kidney transplantation~2. GFR <
19   II,     5.  7.  1|               73 m2 , with or without kidney damage~ ~ ~ ~ ~Table 5.7.
20   II,     5.  7.  1|               CM Code~ ~Treatment~ ~1~Kidney damage~with normal or higher
21   II,     5.  7.  1|               GFR*~>90~585.1~1-5 T if kidney transplant recipient~ ~2~
22   II,     5.  7.  1|              transplant recipient~ ~2~Kidney damage~with mild decrease
23   II,     5.  7.  1|               in GFR*~1529~585.4~ ~5~Kidney failure~<15~(or dialysis)~
24   II,     5.  7.  3|              2. Prevalence of chronic kidney disease per stage in two
25   II,     5.  7.  3|              of stages 3-5 of chronic kidney disease in selected EUGLOREH
26   II,     5.  7.  3|              of stages 3-5 of chronic kidney disease by age and sex.~ ~
27   II,     5.  7.  3|           times as high as that after kidney transplantation: 60% and
28   II,     5.  7.  5|              the problem {14 National Kidney Foundation, 2002 79 /id}.
29   II,     5.  7.  5|         particularly during the World Kidney Day, in the last two years.~·
30   II,     5.  7.  5|               the measurements of the kidney function and the introduction
31   II,     5.  7.  5|          diabetes directly related to kidney disease. This significantly
32   II,     5.  7.  5|             to minimise the imoact of kidney disease in its early stages.~·
33   II,     5.  7.  5|              prevention, dialysis and kidney transplant.~· The Austrian
34   II,     5.  7.  6|          system to provide support to kidney patients.~ ~Monitoring and
35   II,     5.  7.  7|            Diabetes and Digestive and Kidney Diseases; 2005.~Ardissino
36   II,     5.  7.  7|              al (2003): Prevalence of kidney damage in Australian adults:
37   II,     5.  7.  7|        Australian adults: the AusDiab kidney study. J Am Soc Nephrol
38   II,     5.  7.  7|               Prevalence of decreased kidney function in Chinese adults
39   II,     5.  7.  7|           adults aged 35 to 74 years. Kidney Int 2005;68(6):2839-45.~
40   II,     5.  7.  7|             disorders, and awareness. Kidney Int 2006 Aug;70(4):800-6.~
41   II,     5.  7.  7|             DA, et al (2005): Chronic kidney disease awareness, prevalence,
42   II,     5.  7.  7|                de Jong PE (2005): The kidney, a cardiovascular risk marker,
43   II,     5.  7.  7|               new target for therapy. Kidney Int Suppl 2005 Sep;(98):
44   II,     5.  7.  7|              adolescents with chronic kidney disease. Pediatr Nephrol
45   II,     5.  7.  7|     Netherlands: hope for the future? Kidney Int Suppl 2004 Nov;(92):
46   II,     5.  7.  7|               the general population. Kidney Int Suppl 2005 Apr;(94):
47   II,     5.  7.  7|                Hsu CY (2004): Chronic kidney disease and the risks of
48   II,     5.  7.  7|       estimates of utility in chronic kidney disease. Kidney Int 2005
49   II,     5.  7.  7|               chronic kidney disease. Kidney Int 2005 Dec;68(6):2801-
50   II,     5.  7.  7|               relationship of chronic kidney disease prevalence and ESRD
51   II,     5.  7.  7|      Screening strategies for chronic kidney disease in the general population:
52   II,     5.  7.  7|              in patients with chronic kidney disease: focus on end-stage
53   II,     5.  7.  7|              and the risk for chronic kidney disease among nondiabetic
54   II,     5.  7.  7|               risk factors in chronic kidney disease -- evaluating risk
55   II,     5.  7.  7|     filtration rate in adults without kidney disease. J Am Soc Nephrol
56   II,     5.  7.  7|              in children with chronic kidney disease-patient and caregiver
57   II,     5.  7.  7|               Lowel H (2006): Chronic kidney disease and risk of incident
58   II,     5.  7.  7|              27(10):1245-50.~National Kidney Foundation. K/D The seventh
59   II,     5.  7.  7| recommendations for anemia in chronic kidney disease. Am J Kidney Dis
60   II,     5.  7.  7|          chronic kidney disease. Am J Kidney Dis 2006;47(Suppl 3):S1-S145.~
61   II,     5.  7.  7|            Suppl 3):S1-S145.~National Kidney Foundation. K/DOQI clinical
62   II,     5.  7.  7|       practice guidelines for chronic kidney disease: evaluation, classification
63   II,     5.  7.  7|              and stratification. Am J Kidney Dis 2002;39(Supple 1):S1-S266.~
64   II,     5.  7.  7|           Supple 1):S1-S266.~National Kidney Foundation. K/DOQI clinical
65   II,     5.  7.  7|              dyslipidemias in chronic kidney disease. Am J Kidney Dis
66   II,     5.  7.  7|          chronic kidney disease. Am J Kidney Dis 2003;41(suppl 3):S1-S92.~
67   II,     5.  7.  7|             suppl 3):S1-S92.~National Kidney Foundation. K/DOQI clinical
68   II,     5.  7.  7|     metabolism and disease in chronic kidney disease. Am J Kidney Dis
69   II,     5.  7.  7|          chronic kidney disease. Am J Kidney Dis 2003;42(Suppl 3):S1-S202.~
70   II,     5.  7.  7|            Suppl 3):S1-S202.~National Kidney Foundation. K/DOQI clinical
71   II,     5.  7.  7|    antihypertensive agents in chronic kidney disease. Am J Kidney Dis
72   II,     5.  7.  7|          chronic kidney disease. Am J Kidney Dis 2004;43(Suppl 1):S1-S290.~
73   II,     5.  7.  7|              Kausz AT (2002): Chronic kidney disease in the United States:
74   II,     5.  7.  7|           pilot Spanish EPIRCE study. Kidney Int Suppl 2005 Dec;(99):
75   II,     5.  7.  7|           Culleton B, Hamm LL, et al, Kidney disease as a risk factor
76   II,     5.  7.  7|               Association Councils on Kidney in Cardiovascular Disease,
77   II,     5.  7.  7|              medical care for chronic kidney disease and comorbidity
78   II,     5.  7.  7|              R, et al (2007): Chronic kidney disease management in the
79   II,     5.  7.  7|             NEOERICA project results. Kidney Int 2007 Jul;72(1):92-9.~
80   II,     5.  7.  7|              M, et al (2006): Chronic kidney disease and mortality risk:
81   II,     9.  3.  1|       prostate, testis, bowel, liver, kidney, oesophagus and pancreas.
82  III,    10.  2.  1|            Leukemia*~Atherosclerosis*~Kidney and ureter~COPD, asthma
83  III,    10.  2.  1|          Pancreas~- Urinary bladder~- Kidney (renal pelvis and renal
84  III,    10.  2.  1|            and completed in liver and kidney. Therefore, under ideal
85  III,    10.  2.  5|           many substances;~- deceased kidney haematic flow (about 1%
86  III,    10.  4.  2|              animal feed~products~ ~ ~Kidney damage and~urinary tract
87   IV,    11.  5.  4|              Europe represents 17% of kidney transplant activity and
88  Key,   Ap5.  0.  0|                                       kidney~kidneys~knee~knees~